Interim analysis of phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (MBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIS) Meeting Abstract
| Authors: | Lewis, K.; Peris, K.; Sekulic, A.; Stratigos, A.; Dunn, L.; Eroglu, Z.; Chang, A. L.; Migden, M.; Li, S.; Mohan, K.; Coates, E.; Okoye, E.; Baurain, J. F.; Bechter, O.; Hauschild, A.; Butler, M.; Hernandez-Aya, L.; Licitra, L.; Neves, R.; Ruiz, E.; Seebach, F.; Weinreich, D.; Yancopoulos, G.; Lowy, I.; Bowler, T.; Fury, M. |
| Abstract Title: | Interim analysis of phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (MBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIS) |
| Meeting Title: | 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 8 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2020 Nov 9-14 |
| Meeting Location: | Virtual |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2020-11-01 |
| Start Page: | A260 |
| End Page: | A261 |
| Language: | English |
| ACCESSION: | WOS:000616665300416 |
| DOI: | 10.1136/jitc-2020-SITC2020.0428 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 428 -- Source: Wos |
